-- Post-Hoc Analysis of the Phase 2/3 IMPALA Clinical Trial Presented in a Poster Presentation at the CHEST 2026 Annual Meeting --Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company
-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community --
Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare
-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On August 17, 2026, the Compensation
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026
MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively
Data Presented at ATS Showed
-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow® Nebulizer System, Through March 2043
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.
On June 11, 2026, the Compensation Committee
-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer --
-- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026,
-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB)
-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on
Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP):
Biologics License Application (BLA) Filed by the U.S. Food & Drug
